In a phase 1 study, anti-CD7 chimeric antigen receptor (CAR) T cells induced complete remission in children and adults with relapsed or refractory T-cell acute lymphoblastic leukemia (ALL), with 82% ...
Hosted on MSN
CAR7 gene therapy shows promise in T-cell ALL
The use of base editing to generate universal off-the-shelf CAR T cells induced durable remissions -- up to 36 months in one case -- in patients with relapsed or refractory T-cell acute lymphoblastic ...
Fred Hutch Cancer Center scientists have developed an experimental strategy to give genetically engineered CAR T cells help they'd normally find within lymph nodes — but on the go, within the tumor.
CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base ...
Researchers hope to undertake clinical studies in multiple cancers, including ovarian cancer, glioblastoma, and others.
Allogeneic stem cell transplantation in chronic myelomonocytic leukemia: Analysis of post-transplant survival and risk factors in 138 Mayo Clinic patients. This is an ASCO Meeting Abstract from the ...
The National Institute for Health and Care Excellence (NICE) has recommended obecabtagene autoleucel (obe-cel) for adults aged 26 and older with relapsed or refractory B-cell precursor acute ...
At the recent American Society of Hematology annual meeting, researchers presented preclinical data examining how transdifferentiation between hematopoietic lineages -- driven by LMO2 expression and ...
Infusion of base-edited CAR7 T cells for T-cell acute lymphoblastic leukemia enabled 82% of patients in a phase I study to achieve a deep remission after receiving the therapy, allowing them to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results